Solid Tumor Cancer Whole Blood
About: Solid Tumor Whole Blood samples are obtained from donors with confirmed solid tumors. Valuable for transcriptomic and genomic analysis, immune profiling, and identifying systemic molecular alterations in cancer.
Solid Tumor Cancer Whole Blood
Fresh Solid Tumor Cancer Whole Blood is collected from IRB-consented donors with clinically confirmed Solid Tumor Cancer. These fresh samples are ideal for immunological and translational research focused on solid tumor cancer pathogenesis, inflammation, and biomarker discovery.
Product Features
- Fresh whole blood from clinically diagnosed Solid Tumor Cancer donors
- Custom tubes and anticoagulants available
- Collected and shipped same-day for maximum freshness
- Research Use Only (RUO)
De-identified Donor Data
- Confirmed Solid Tumor Cancer diagnosis by physician or specialist
- Demographic details: age, sex assigned at birth, ethnicity
- Medical history including allergies and infectious disease status
Applications
- Immunophenotyping of immune cell populations in solid tumor cancer
- Gene expression and transcriptomic analysis
- Inflammatory marker and cytokine profiling
- Drug response and mechanism-of-action studies
Compliance and Quality
- IRB-approved protocols and electronic informed consent
- HIPAA-compliant data management
Ordering and Customization
Solid Tumor Cancer whole blood is available in a range of standard and custom volumes. For international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations.
Whole Blood
Frequently Asked Questions
1 Answer
Collected and shipped same-day – local pickup may be available. For more information, request a quote or contact: LearnMore@sanguinebio.com
1 Answer
YES – The same-day program processes and ships samples on the day of collection, ensuring delivery well within 48 hours for the designated service areas.
Ask a Question
Need a custom Whole Blood cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.